Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.49 |
| ▸ | GHSR | Q92847 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3080123 | 0.88 | GHSR (0.53) | TP53GHSRMAPK1SMN1; SMN2POLB | |
| SCHEMBL3069134 | 0.88 | GHSR (0.54) | GHSR | |
| SCHEMBL3069681 | 0.87 | GHSR (0.54) | GHSRPOLB | |
| SCHEMBL3069093 | 0.87 | GHSR (0.51) | TP53GHSRMAPK1SMN1; SMN2TSHR | |
| SCHEMBL3072269 | 0.87 | GHSR (0.48) | TP53GHSRPOLB | |
| SCHEMBL3077104 | 0.87 | GHSR (0.48) | TP53GHSRCYP3A4CYP2C19 | |
| SCHEMBL3072735 | 0.85 | GHSR (0.45) | TP53GHSRPOLB | |
| SCHEMBL3069649 | 0.85 | GHSR (0.50) | TP53GHSRPOLB | |
| SCHEMBL3074334 | 0.85 | GHSR (0.47) | TP53GHSR | |
| SCHEMBL3261334 | 0.85 | GHSR (0.47) | TP53GHSRCYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951675-B1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-03-20 | — | — | EP | disclosed |
| US-7790745-B2 | Tetrahydroisoquinoline LXR Modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | NR1H2, NR1H3, NR1I2 | TP53 3851/4885GHSR 351/4885MAPK1 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.